z-logo
open-access-imgOpen Access
Human iPSC differentiation to retinal organoids in response to IGF1 and BMP4 activation is line‐ and method‐dependent
Author(s) -
Chichagova Valeria,
Hilgen Gerrit,
Ghareeb Ali,
Georgiou Maria,
Carter Madeleine,
Sernagor Evelyne,
Lako Majlinda,
Armstrong Lyle
Publication year - 2020
Publication title -
stem cells
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.159
H-Index - 229
eISSN - 1549-4918
pISSN - 1066-5099
DOI - 10.1002/stem.3116
Subject(s) - biology , organoid , induced pluripotent stem cell , retinal , microbiology and biotechnology , retina , cellular differentiation , neuroscience , embryonic stem cell , genetics , gene , biochemistry
Induced pluripotent stem cell (iPSC)‐derived retinal organoids provide a platform to study human retinogenesis, disease modeling, and compound screening. Although retinal organoids may represent tissue structures with greater physiological relevance to the in vivo human retina, their generation is not without limitations. Various protocols have been developed to enable development of organoids with all major retinal cell types; however, variability across iPSC lines is often reported. Modulating signaling pathways important for eye formation, such as those involving bone morphogenetic protein 4 (BMP4) and insulin‐like growth factor 1 (IGF1), is a common approach used for the generation of retinal tissue in vitro. We used three human iPSC lines to generate retinal organoids by activating either BMP4 or IGF1 signaling and assessed differentiation efficiency by monitoring morphological changes, gene and protein expression, and function. Our results showed that the ability of iPSC to give rise to retinal organoids in response to IGF1 and BMP4 activation was line‐ and method‐dependent. This demonstrates that careful consideration is needed when choosing a differentiation approach, which would also depend on overall project aims.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here